GLP-1, Obesity and Biotech Stocks, Rated

Ranked by composite score

Ranked highest to lowest by MELANY composite score, a 0 to 100 reading from eight factors. Each row links to the full breakdown and the live price. Ratings are a dated snapshot, most recently computed 2026-10-07.

These tiers are algorithmic research readings, not a recommendation to buy or sell any security, and not personalized investment advice. Ranking order is not a suggested purchase order.

What is in the app for these 20 companies

The score and the eight factors behind it are open on every company page. The trade plan is the part that is not: one suggested entry price per company, the stop, the targets, and an alert when a name enters its entry zone. That is part of Market Eyes Pro, and the first 30 days are free.

What moves this group

For the incumbents, manufacturing capacity, payer coverage and pricing pressure matter more than trial news. For the clinical-stage names, a single trial readout can reset the entire valuation, which is why their catalyst factor dominates and their scores are volatile. Patent timelines and the arrival of oral formulations are the structural swing factors for the group.

Also searched as: GLP-1 stocks, weight loss drug companies, obesity drug makers, biotech shares.

How Market Eyes Live scores these companies

Every company on this page is scored by MELANY, our own engine, which reads regulatory filings and market data and produces a composite score from 0 to 100 across eight factors: valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile and macro fit.

Each score maps to a conviction tier rather than a buy or sell call. Established companies with enough financial history are judged on fundamentals. Pre-profit or thin-data companies are judged on a separate speculative path that leans on momentum and theme strength, because there are not enough fundamentals to read. That is why two names with similar scores can carry very different risk.

The engine is not new to being tested. MELANY's risk and portfolio rules are stress-tested across 19 years of U.S. market history, from 2007 to 2026, spanning the 2008 financial crisis, the 2020 COVID crash and the 2022 bear market, and the test set includes companies that later delisted so the results are not flattered by survivorship. Every rating it publishes is also recorded and graded every day against what the market does next. The full methodology and the validation study are public: how MELANY is tested and the MELANY validation study, Working Paper No. 01.

Frequently asked questions

Other sectors and themes